Next Article in Journal
TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis
Next Article in Special Issue
A Burkholderia pseudomallei Outer Membrane Vesicle Vaccine Provides Cross Protection against Inhalational Glanders in Mice and Non-Human Primates
Previous Article in Journal
Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria
Previous Article in Special Issue
A Review of the Safety and Efficacy of Vaccines as Prophylaxis for Clostridium difficile Infections
Article Menu

Export Article

Open AccessArticle
Vaccines 2017, 5(4), 33; doi:10.3390/vaccines5040033

Characterization of the Burkholderia cenocepacia TonB Mutant as a Potential Live Attenuated Vaccine

1
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA
2
Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Toshi Nagata
Received: 2 September 2017 / Revised: 19 September 2017 / Accepted: 26 September 2017 / Published: 28 September 2017
(This article belongs to the Special Issue Vaccines Against Chronic and Persistent Bacterial Infections)
View Full-Text   |   Download PDF [1249 KB, uploaded 28 September 2017]   |  

Abstract

Burkholderia cenocepacia is an opportunistic pathogen prevalent in cystic fibrosis patients, which is particularly difficult to treat, causing chronic and eventually fatal infections. The lack of effective treatment options makes evident the need to develop alternative therapeutic or prophylactic approaches. Vaccines, and live attenuated vaccines, are an unexplored avenue to treat B. cenocepacia infections. Here we constructed and characterized a B. cenocepacia tonB mutant strain, which was unable to actively transport iron, to test whether this single gene deletion mutant (strain renamed GAP001) protected against an acute respiratory B. cenocepacia lethal infection. Here we show that the mutant strain GAP001 is attenuated, and effective at protecting against B. cenocepacia challenge. Intranasal administration of GAP001 to BALB/c mice resulted in almost complete survival with high degree of bacterial clearance. View Full-Text
Keywords: Burkholderia cenocepacia; tonB; attenuated strain; vaccine Burkholderia cenocepacia; tonB; attenuated strain; vaccine
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Pradenas, G.A.; Myers, J.N.; Torres, A.G. Characterization of the Burkholderia cenocepacia TonB Mutant as a Potential Live Attenuated Vaccine. Vaccines 2017, 5, 33.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top